The Staging of Major Mood Disorders: Clinical and Neurobiological Correlates

키워드

참고문헌 (70)

1. Korf J, "Delayed mood transitions in major depressive disorder", Med Hypotheses, 82, pp.581~588 (2014)[DOI]
2. Cosci F, "Staging of mental disorders: systematic review", Psychother Psychosom, 82, pp.20~34 (2013)[DOI]
3. Zhang L, "Duration of untreated bipolar disorder: a multicenter study", Sci Rep, 7, pp.44811~ (2017)[DOI]
4. Mwangi B, "Individualized prediction and clinical staging of bipolar disorders using neuroanatomical biomarkers", Biol Psychiatry Cogn Neurosci Neuroimaging, 1, pp.186~194 (2016)[DOI]
5. Slyepchenko A, "T helper 17 cells may drive neuroprogression in major depressive disorder: proposal of an integrative model", Neurosci Biobehav Rev, 64, pp.83~100 (2016)[DOI]
6. Fernandes BS, "Staging in bipolar disorder: one step closer to precision psychiatry", Rev Bras Psiquiatr, 39, pp.88~89 (2017)[DOI]
7. Zivanovic O, "Kraepelin's concept of manic-depressive insanity: one hundred years later", J Affect Disord, 137, pp.15~24 (2012)[DOI]
8. Passos IC, "Should bipolar disorder treatment be modified depending on staging?", Expert Rev Neurother, 17, pp.93~95 (2017)[DOI]
9. Ather Muneer, "Staging Models in Bipolar Disorder: A Systematic Review of the Literature", Clinical Psychopharmacology and Neuroscience, 14(2), pp.117~130 (2016), 대한정신약물학회
10. Duffy A, "The developmental trajectory of bipolar disorder", Br J Psychiatry, 204, pp.122~128 (2014)[DOI]
11. Duffy A, "Childhood anxiety: an early predictor of mood disorders in offspring of bipolar parents", J Affect Disord, 150, pp.363~369 (2013)[DOI]
12. Kupfer DJ, "Staging bipolar disorder: what data and what models are needed?", Lancet Psychiatry, 2, pp.564~570 (2015)[DOI]
13. Garnham J, "Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study", J Affect Disord, 104, pp.185~190 (2007)[DOI]
14. Duffy A, "A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical profile?", Can J Psychiatry, 52, pp.369~376 (2007)[DOI]
15. Watanabe Y, "Long-term efficacy and safety of lamotrigine for all types of bipolar disorder", Neuropsychiatr Dis Treat, 13, pp.843~854 (2017)[DOI]
16. Pearlson GD, "Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder", Annu Rev Clin Psychol, 11, pp.251~281 (2015)[DOI]
17. Arango C, "Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders", Schizophr Bull, 40(Suppl 2), pp.S138~S146 (2014)[DOI]
18. Walker AJ, "Stress, inflammation, and cellular vulnerability during early stages of affective disorders: biomarker strategies and opportunities for prevention and intervention", Front Psychiatry, 5, pp.34~ (2014)
19. Lim CS, "Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence", Neurosci Biobehav Rev, 37, pp.418~435 (2013)[DOI]
20. Tondo L, "Bipolar disorders following initial depression: modeling predictive clinical factors", J Affect Disord, 167, pp.44~49 (2014)[DOI]
21. Duffy A, "How does a developmental perspective inform us about the early natural history of bipolar disorder?", J Can Acad Child Adolesc Psychiatry, 22, pp.6~12 (2013)
22. Benarous X, "Early interventions for youths at high risk for bipolar disorder: a developmental approach", Eur Child Adolesc Psychiatry, 25, pp.217~233 (2016)[DOI]
23. Duffy A, "The early manifestations of bipolar disorder: a longitudinal prospective study of the offspring of bipolar parents", Bipolar Disord, 9, pp.828~838 (2007)[DOI]
24. Duffy A, "Early stages in the development of bipolar disorder", J Affect Disord, 121, pp.127~135 (2010)[DOI]
25. Berk M, "Staging in bipolar disorder: from theoretical framework to clinical utility", World Psychiatry, 16, pp.236~244 (2017)[DOI]
26. Duffy A, "The early natural history of bipolar disorder: what we have learned from longitudinal high-risk research", Can J Psychiatry, 55, pp.477~485 (2010)[DOI]
27. Silarova B, "Metabolic syndrome in patients with bipolar disorder:comparison with major depressive disorder and non-psychiatric controls", J Psychosom Res, 78, pp.391~398 (2015)[DOI]
28. Woo YS, "A diagnosis of bipolar spectrum disorder predicts diagnostic conversion from unipolar depression to bipolar disorder: a 5-year retrospective study", J Affect Disord, 174, pp.83~88 (2015)[DOI]
29. Colle R, "Depressed suicide attempters have smaller hippocampus than depressed patients without suicide attempts", J Psychiatr Res, 61, pp.13~18 (2015)[DOI]
30. da Costa SC, "Refractory bipolar disorder and neuroprogression", Prog Neuropsychopharmacol Biol Psychiatry, 70, pp.103~110 (2016)[DOI]
31. Kessing LV, "Evidence for clinical progression of unipolar and bipolar disorders", Acta Psychiatr Scand, 135, pp.51~64 (2017)[DOI]
32. Gama CS, "Staging and neuroprogression in bipolar disorder: a systematic review of the literature", Rev Bras Psiquiatr, 35, pp.70~74 (2013)[DOI]
33. Vavakova M, "Markers of oxidative stress and neuroprogression in depression disorder", Oxid Med Cell Longev, 2015, pp.898393~ (2015)
34. Moylan S, "The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications", Mol Psychiatry, 18, pp.595~606 (2013)[DOI]
35. Vieta E, "The clinical implications of cognitive impairment and allostatic load in bipolar disorder", Eur Psychiatry, 28, pp.21~29 (2013)
36. Ramsay DS, "Clarifying the roles of homeostasis and allostasis in physiological regulation", Psychol Rev, 121, pp.225~247 (2014)[DOI]
37. Grande I, "Mediators of allostasis and systemic toxicity in bipolar disorder", Physiol Behav, 106, pp.46~50 (2012)[DOI]
38. Berk M, "Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors", Neurosci Biobehav Rev, 35, pp.804~817 (2011)[DOI]
39. Wu MJ, "Identification and individualized prediction of clinical phenotypes in bipolar disorders using neurocognitive data, neuroimaging scans and machine learning", Neuroimage, 145, pp.254~264 (2017)[DOI]
40. Quigley SJ, "Volume and shape analysis of subcortical brain structures and ventricles in euthymic bipolar I disorder", Psychiatry Res, 233, pp.324~330 (2015)[DOI]
41. Brown ES, "Association of depressive symptoms with hippocampal volume in 1936 adults", Neuropsychopharmacology, 39, pp.770~779 (2014)[DOI]
42. Wise T, "Common and distinct patterns of grey-matter volume alteration in major depression and bipolar disorder: evidence from voxel-based meta-analysis", Mol Psychiatry, 22, pp.1455~1463 (2017)[DOI]
43. Niu M, "Common and specific abnormalities in cortical thickness in patients with major depressive and bipolar disorders", EBioMedicine, 16, pp.162~171 (2017)[DOI]
44. Beyer JL, "Hyperintense MRI lesions in bipolar disorder: a meta-analysis and review", Int Rev Psychiatry, 21, pp.394~409 (2009)[DOI]
45. Fernandes BS, "Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies", BMC Med, 13, pp.289~ (2015)[DOI]
46. Fernandes BS, "Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis", J Psychiatr Res, 45, pp.995~1004 (2011)[DOI]
47. Fernandes BS, "Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis", J Psychiatr Res, 43, pp.1200~1204 (2009)[DOI]
48. Kapczinski F, "The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers", Acta Neuropsychiatr, 21, pp.272~274 (2009)[DOI]
49. Moniczewski A, "Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 1. Chemical aspects and biological sources of oxidative stress in the brain", Pharmacol Rep, 67, pp.560~568 (2015)[DOI]
50. Brown NC, "An updated meta-analysis of oxidative stress markers in bipolar disorder", Psychiatry Res, 218, pp.61~68 (2014)[DOI]
51. Siwek M, "Thiobarbituric acid-reactive substances: markers of an acute episode and a late stage of bipolar disorder", Neuropsychobiology, 73, pp.116~122 (2016)[DOI]
52. Andreazza AC, "3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder", J Psychiatry Neurosci, 34, pp.263~271 (2009)
53. Soeiro-de-Souza MG, "Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder", Int J Neuropsychopharmacol, 16, pp.1505~1512 (2013)[DOI]
54. Lima IM, "Analysis of telomere attrition in bipolar disorder", J Affect Disord, 172, pp.43~47 (2015)[DOI]
55. Berk M, "Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial", BMC Med, 10, pp.91~ (2012)[DOI]
56. Wada A, "Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades", J Pharmacol Sci, 110, pp.14~28 (2009)[DOI]
57. Kapczinski F, "A systemic toxicity index developed to assess peripheral changes in mood episodes", Mol Psychiatry, 15, pp.784~786 (2010)[DOI]
58. Milanovic D, "The fas ligand", fas death receptor pathways contribute to propofol-induced apoptosis and neuroinflammation in the brain of neonatal rats, 2016, pp.30, 434~452
59. Luo Y, "Altered serum levels of TNF-<TEX>${\alpha}$<", TEX>, IL-6 and IL-18 in manic, depressive, mixed state of bipolar disorder patients, 2016, pp.244, 19~23
60. Uyanik V, "Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment", Psychiatry Res, 228, pp.386~392 (2015)[DOI]
61. Tatay-Manteiga A, "Clinical staging and serum cytokines in bipolar patients during euthymia", Prog Neuropsychopharmacol Biol Psychiatry, 77, pp.194~201 (2017)[DOI]
62. Pandey GN, "Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain", Mod Trends Pharmacopsychiatry, 31, pp.79~95 (2017)
63. de Melo LGP, "Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders", Prog Neuropsychopharmacol Biol Psychiatry, 78, pp.34~50 (2017)[DOI]
64. SayuriYamagata A, "Medical comorbidity in bipolar disorder: the link with metabolic-inflammatory systems", J Affect Disord, 211, pp.99~106 (2017)[DOI]
65. Berk M, "Stage managing bipolar disorder", Bipolar Disord, 16, pp.471~477 (2014)[DOI]
66. Kapczinski F, "Clinical implications of a staging model for bipolar disorders", Expert Rev Neurother, 9, pp.957~966 (2009)[DOI]
67. Duffy A, "Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence", Can J Psychiatry, 59, pp.659~666 (2014)[DOI]
68. Ferensztajn E, "Staging of unipolar affective illness", Psychiatr Pol, 48, pp.1127~1141 (2014)[DOI]
69. Scott J, "Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value", Br J Psychiatry, 202, pp.243~245 (2013)[DOI]
70. Duffy A, "Do the trajectories of bipolar disorder and schizophrenia follow a universal staging model?", Can J Psychiatry, 62, pp.115~122 (2017)[DOI]

관련 논문AI추천